Special Issue "Molecular Biology of Melanoma 2.0"
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 9786
Interests: human malignant melanoma; genomic alterations; gene expression alterations; chromosome copy number alterations; array CGH; FISH
Special Issues, Collections and Topics in MDPI journals
Special Issue in Biomedicines: Diagnostics and Therapeutics of Melanoma
Cutaneous melanoma is one of the most invasive and metastatic human cancers, and accounts for the majority of skin cancer deaths despite comprising less than 5% of all cutaneous malignancies . Although local excision for early-stage primary melanoma offers the best chance of cure, recent advances in molecular genetics and genomics have revolutionized the management and treatment of late-stage and metastatic melanomas, leading to significant improvements in clinical outcomes . Approximately 40%–50% of melanomas harbour an activating mutation in the BRAF oncogene, which constitutively activates the mitogen-activated protein kinase (MAPK) pathway. The targeted inhibition of the mutant BRAF gene is one of the most promising therapeutic approaches for patients with unresectable or metastatic melanoma. BRAF inhibitors have high response rates amongst patients with advantaged state melanomas. Unfortunately, despite the 6–8 month median progression-free survival, most patients develop resistance and experience tumour re-growth. However, the recent successes of single-agent and combination therapies are promising; improving the currently existing classification schemes of patients for the appropriate treatment as well as understanding the mechanism of therapeutic resistance are still crucial goals. Chemoresistance as well as a high metastatic potential are supposed to be in association with the fact that melanocytes are derived from highly motile neural crest precursors . Different invasion strategies can be used by melanoma cells, depending on varying environmental effects, to invade the surrounding and distant tissues. While new agents are already used to successfully treat malignant melanomas, a more personalized approach incorporating genomic, proteomic, and immunologic data are needed for successful therapeutic decisions .
- Clin Exp Metastasis. 2018 Aug;35(5-6):379-391.
- Br J Surg. 2018 Jan;105(2):e31-e47.
- Cancer Metastasis Rev. 2017 Mar;36(1):7-21.
- Expert Opin Pharmacother. 2017 Apr;18(5):487-495.
Prof. Dr. Balázs Margit
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- genomic alterations
- invasion related molecular markers
- driver genes
- personalized therapies
- BRAF inhibitors